Pasithea Therapeutics Corp Stock Current Ratio
| KTTA Stock | USD 2.90 0.11 3.65% |
Pasithea Therapeutics Corp fundamentals help investors to digest information that contributes to Pasithea Therapeutics' financial success or failures. It also enables traders to predict the movement of Pasithea Stock. The fundamental analysis module provides a way to measure Pasithea Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pasithea Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 6.34 | 6.02 |
Pasithea | Current Ratio |
Pasithea Therapeutics Corp Company Current Ratio Analysis
Pasithea Therapeutics' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Pasithea Therapeutics Current Ratio | 51.17 X |
Most of Pasithea Therapeutics' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pasithea Therapeutics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Pasithea Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Pasithea Therapeutics is extremely important. It helps to project a fair market value of Pasithea Stock properly, considering its historical fundamentals such as Current Ratio. Since Pasithea Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pasithea Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pasithea Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Pasithea Current Ratio Historical Pattern
Today, most investors in Pasithea Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Pasithea Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Pasithea Therapeutics current ratio as a starting point in their analysis.
Pasithea Therapeutics Current Ratio |
| Timeline |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
Pasithea Price To Sales Ratio
Price To Sales Ratio |
|
In accordance with the recently published financial statements, Pasithea Therapeutics Corp has a Current Ratio of 51 times. This is much higher than that of the Biotechnology sector and notably higher than that of the Health Care industry. The current ratio for all United States stocks is notably lower than that of the firm.
Pasithea Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pasithea Therapeutics' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pasithea Therapeutics could also be used in its relative valuation, which is a method of valuing Pasithea Therapeutics by comparing valuation metrics of similar companies.Pasithea Therapeutics is currently under evaluation in current ratio category among its peers.
Pasithea Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pasithea Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pasithea Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Pasithea Fundamentals
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | (8.3 M) | ||||
| Shares Outstanding | 1.27 M | ||||
| Shares Owned By Insiders | 23.12 % | ||||
| Shares Owned By Institutions | 2.86 % | ||||
| Number Of Shares Shorted | 5.11 K | ||||
| Price To Book | 0.21 X | ||||
| Price To Sales | 42.15 X | ||||
| Revenue | 486.56 K | ||||
| Gross Profit | (2.21 K) | ||||
| EBITDA | (15.33 M) | ||||
| Net Income | (15.51 M) | ||||
| Cash And Equivalents | 47.94 M | ||||
| Cash Per Share | 1.80 X | ||||
| Total Debt | 81.68 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 51.17 X | ||||
| Book Value Per Share | 22.46 X | ||||
| Cash Flow From Operations | (13.43 K) | ||||
| Short Ratio | 0.32 X | ||||
| Earnings Per Share | (14.79) X | ||||
| Target Price | 2.0 | ||||
| Beta | 0.82 | ||||
| Market Capitalization | 3.67 M | ||||
| Total Asset | 26.12 M | ||||
| Retained Earnings | (35.32 M) | ||||
| Working Capital | 14.06 M | ||||
| Net Asset | 26.12 M |
About Pasithea Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pasithea Therapeutics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pasithea Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pasithea Therapeutics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pasithea Therapeutics is a strong investment it is important to analyze Pasithea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pasithea Therapeutics' future performance. For an informed investment choice regarding Pasithea Stock, refer to the following important reports:Check out Pasithea Therapeutics Piotroski F Score and Pasithea Therapeutics Altman Z Score analysis. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. If investors know Pasithea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pasithea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (14.79) | Revenue Per Share 0.37 | Quarterly Revenue Growth 14.981 | Return On Assets (0.38) | Return On Equity (0.63) |
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pasithea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pasithea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pasithea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.